In accordance with FAR subpart 6.302-1(c) (ii), the Centers for Disease Control and Prevention (CDC) intends to issue a sole Purchase Order for MagNa Pure Reagents. Reagents for CDC DHQP - study continuity from Roche Diagnostics. Assays and specimen collection procedures used in the study protocol were validated explicitly using materials purchased from Roche Diagnostics. These materials have been evaluated for effectiveness, value, and ease of use, and similar studies conducted previously utilized these materials. In order to ensure data is comparable from, it is crucial to maintain consistency in laboratory testing. The use of products available through another company could potentially compromise the comparability of data from this and other country-wide prevalence studies. Because these studies are intended to monitor the burden of disease in country, comparability of results is crucial to guide development of interventions and treatment algorithms. It is the understanding of the Government that an award to any other source would cause unacceptable delays in meeting the requirements of the Government. Interested parties who feel that they possess the capabilities to provide the services described above should submit a capability statement demonstrating their abilities to provide the services. The information received in response to this notice will be considered solely for the purpose of determining whether or not to conduct a competitive requirement. Please send your documentation to Phil Alexander by fax (770) 488-2067, or email to [email protected]. Documentation should be received within fifteen (10) days after the date of publication of this synopsis to be considered by CDC. A determination by the CDC not to compete this proposed contract, based upon responses to this notification, is solely within discretion of the government.

Bid Protests Not Available